Compare Amphastar Pharmaceuticals Inc (AMPH) vs ING Groep NV (ING) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs ING Groep NV — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.44 (market cap $863.95M), while ING Groep NV trades at $35.38 (market cap $101.24B). The key difference: ING Groep NV is far larger — about 117.2× Amphastar Pharmaceuticals Inc's market cap, and ING Groep NV pays a 3.74% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | ING | |
|---|---|---|
Market Cap | $863.95M | $101.24B |
Sector | Health | Financials |
52-Week High | $30.81 | $35.92 |
52-Week Low | $16.87 | $23.66 |
Enterprise Value | $1.26B | — |
Dividend Yield | — | 3.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
ING trades at $35.68, down slightly by 0.08% on the day, with a bullish technical signal from moving averages and a neutral oscillator reading. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.79 versus $0.75 expected, and raised its full-year revenue guidance. Analyst consensus is strongly positive with 10 buy ratings and no sell ratings out of 16 analysts.
The outlook for ING is favorable, supported by earnings momentum and strategic initiatives, though risks include negative cash flow trends and potential market volatility. The stock presents a value opportunity with a P/E of 13.37 and a net income margin of 28.34%, but investors should weigh the persistent cash flow deficits against growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →
